BIOTECH Logo

BIOTECH

A biotechnology group offering preclinical services, intein development, and licensing.

BST | BME Growth

Overview

Corporate Details

ISIN(s):
ES0184980003 (+1 more)
LEI:
959800GNYT6ZZEWPEW29
Country:
Spain
Address:
AVDA. DEL DESARROLLO TECNOLOGICO (PARQUE CIENTIFICO TECNOLOGICO AGROINDUSTRIAL) 11, 11591 Jerez de la Frontera

Description

Biotechnology Assets Biat Group is a biotechnology corporate group with a global commercial structure operating through several subsidiaries. Its subsidiary Biobide is a provider of preclinical services, specializing in tailor-made toxicity and efficacy testing using the zebrafish (ZF) animal model. ZIP Solutions develops and promotes a proprietary set of inteins for high-value industrial applications, including gene therapy, immunotherapy, in-vitro diagnostics, smart vaccines (RNA & DNA), and affinity-based protein purification. The Bionatur division manages biotech assets for human and animal health. The group focuses on licensing its platforms and products, conducting preclinical research, and improving recombinant and DNA vaccines through collaborations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-03-19 14:18
Net Asset Value(s)
English 4.0 KB
2025-03-18 10:30
Net Asset Value(s)
English 4.0 KB
2025-03-17 14:38
Net Asset Value(s)
English 4.0 KB
2025-03-14 10:53
Net Asset Value(s)
English 4.0 KB
2025-03-13 15:33
Net Asset Value(s)
English 4.0 KB
2025-03-12 14:50
Net Asset Value(s)
English 4.1 KB
2025-03-11 15:54
Net Asset Value(s)
English 4.0 KB
2025-03-10 14:35
Net Asset Value(s)
English 4.0 KB
2025-03-07 14:28
Net Asset Value(s)
English 4.0 KB
2025-03-07 09:08
Net Asset Value(s)
English 4.0 KB
2025-03-06 15:30
Net Asset Value(s)
English 4.0 KB
2025-03-06 08:00
Net Asset Value(s)
English 4.0 KB
2025-03-05 14:34
Net Asset Value(s)
English 4.0 KB
2025-03-04 14:40
Net Asset Value(s)
English 4.0 KB
2025-03-03 15:43
Net Asset Value(s)
English 4.0 KB

Automate Your Workflow. Get a real-time feed of all BIOTECH filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BIOTECH

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BIOTECH via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Genprex, Inc. Logo
Clinical-stage gene therapy company developing therapies for cancer and diabetes.
United States of America
GNPX
Genxone Spolka Akcyjna Logo
A biotechnology company specializing in Next Generation Sequencing and medical diagnostics.
Poland
GX1
GeoVax Labs, Inc. Logo
Clinical-stage biotech developing vaccines and therapies for infectious diseases and cancer.
United States of America
GOVX
GH Research PLC Logo
Develops mebufotenin-based therapies for psychiatric and neurological disorders.
United States of America
GHRS
GI Innovation Inc. Logo
Researches and develops protein-based drugs for immuno-oncology and immunology.
South Korea
358570
Ginkgo Bioworks Holdings, Inc. Logo
Operates a horizontal platform for cell programming and synthetic biology.
United States of America
DNA
GRAIL, Inc. Logo
A healthcare company developing blood tests for multi-cancer early detection.
United States of America
GRAL
GT Biopharma, Inc. Logo
Clinical-stage immuno-oncology company developing therapies with its NK cell engager tech.
United States of America
GTBP
Guard Therapeutics International AB Logo
Clinical-stage biotech developing therapies to prevent acute kidney injury.
Sweden
GUARD
Gubra A/S Logo
Biotech and CRO focused on peptide drugs for metabolic and fibrotic diseases.
Denmark
GUBRA

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.